Search results
Results from the WOW.Com Content Network
In medicine, proton therapy, or proton radiotherapy, is a type of particle therapy that uses a beam of protons to irradiate diseased tissue, most often to treat cancer.The chief advantage of proton therapy over other types of external beam radiotherapy is that the dose of protons is deposited over a narrow range of depth; hence in minimal entry, exit, or scattered radiation dose to healthy ...
Particle therapy is a form of external beam radiotherapy using beams of energetic neutrons, protons, or other heavier positive ions for cancer treatment. The most common type of particle therapy as of August 2021 is proton therapy. [1]
The $100-million proton therapy center is the first such treatment facility in central Ohio for adult and pediatric cancer patients. Ohio State, Nationwide Children's proton therapy center brings ...
Proton beam therapy has been shown to be just as effective as traditional chemotherapy, with fewer side effects and less treatment time. High-dose proton radiation could shorten breast cancer ...
Some α emitting isotopes such as 225 Ac and 213 Bi are only available in limited quantities from 229 Th decay, although cyclotron production is feasible. [9] [10] [11] Among alpha-emitting radiometals according to availability, chelation chemistry, and half-life, 212 Pb is also a promising candidate for targeted alpha-therapy.
Medicine has used radiation therapy as a treatment for cancer for more than 100 years, with its earliest roots traced from the discovery of X-rays in 1895 by Wilhelm Röntgen. [119] Emil Grubbe of Chicago was possibly the first American physician to use X-rays to treat cancer, beginning in 1896. [120]
Angioimmunoblastic T-cell lymphoma (AITL, sometimes misspelled AILT, formerly known as "angioimmunoblastic lymphadenopathy with dysproteinemia" [2]: 747 ) is a mature T-cell lymphoma of blood or lymph vessel immunoblasts characterized by a polymorphous lymph node infiltrate showing a marked increase in follicular dendritic cells (FDCs) and high endothelial venules (HEVs) and systemic involvement.
Developed by IDEC Pharmaceuticals, now part of Biogen Idec, [8] ibritumomab tiuxetan was the first radioimmunotherapy drug approved by the US Food and Drug Administration (FDA) in 2002 to treat cancer. It was approved for the treatment of people with relapsed or refractory, low‑grade or follicular B‑cell non‑Hodgkin's lymphoma (NHL ...